FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to the chemical-pharmaceutical industry and provides pharmaceutical compositions for pulmonary delivery, comprising levodopa particles, having a geometric size of more than 5 mcm, in particular 8 to 12 mcm; tap density less than 0.075 g/cm3, in particular from 0.025 to about 0.050 g/cm3; and water content of 1.90 to 2.90 percent by weight.
EFFECT: group of inventions improves the stability of the pharmaceutical composition by decreasing the water content of the composition.
21 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE | 2013 |
|
RU2676093C2 |
| REDUCTION OF INPATIENT VARIABILITY OF LEVODOPA CONCENTRATIONS IN BLOOD PLASMA | 2013 |
|
RU2682681C2 |
| LEVODOPA FORMULATIONS FOR RAPID RELIEF OF PARKINSON'S DISEASE | 2013 |
|
RU2685718C2 |
| DRY POWDER FORMULATIONS AND METHODS OF TREATING PULMONARY DISEASES | 2010 |
|
RU2577698C2 |
| METHODS OF TREATING FUNGAL INFECTIONS | 2019 |
|
RU2820457C2 |
| PHARMACEUTICAL COMPOSITIONS | 2004 |
|
RU2364400C2 |
| ANTIFUNGAL DRY POWDERS | 2017 |
|
RU2766086C2 |
| RAPID REDUCTION OF MOTOR FLUCTUATIONS ACCOMPANYING PARKINSON'S DISEASE | 2014 |
|
RU2698330C2 |
| CATIONS OF MONOVALENT METALS OF DRY POWDERS FOR INHALATIONS | 2011 |
|
RU2640921C2 |
| INHALATION COMPOSITIONS CONTAINING MONTELEUKAST ACID AND PDE-4 INHIBITOR OR INHALATION CORTICOSTEROID | 2008 |
|
RU2470639C2 |
